Abstract | OBJECTIVES: DESIGN: SETTING AND PATIENTS: INTERVENTIONS: MEASUREMENTS AND MAIN RESULTS: The incremental cost-effectiveness of linezolid was calculated as the additional quality-adjusted life-years resulting from therapy with linezolid divided by the sum of the incremental costs arising because of use of linezolid (e.g., higher direct costs for linezolid, costs per in-hospital care of survivors, and posthospitalization costs). Despite its higher cost, linezolid was cost-effective for treatment of ventilator-associated pneumonia. The cost per quality-adjusted life-year equals approximately 30,000 dollars. The model was moderately sensitive to the estimated efficacy of linezolid over vancomycin. Nonetheless, even with all inputs simultaneously skewed against, linezolid remains a cost-effective option (cost per quality-adjusted life-year approximately 100,000 dollars). Based on Monte Carlo simulation, the results of our analysis are robust across a range of model inputs and assumptions (95% confidence interval for cost per quality-adjusted life-year ranges from 23,637 dollars to 42,785 dollars). CONCLUSIONS:
|
Authors | Andrew F Shorr, Gregory M Susla, Marin H Kollef |
Journal | Critical care medicine
(Crit Care Med)
Vol. 32
Issue 1
Pg. 137-43
(Jan 2004)
ISSN: 0090-3493 [Print] United States |
PMID | 14707572
(Publication Type: Comparative Study, Journal Article)
|
Chemical References |
- Acetamides
- Oxazolidinones
- Vancomycin
- Linezolid
|
Topics |
- Acetamides
(economics, therapeutic use)
- Cohort Studies
- Cost-Benefit Analysis
- Drug Costs
- Female
- Hospital Costs
- Humans
- Intensive Care Units
- Linezolid
- Male
- Oxazolidinones
(economics, therapeutic use)
- Pneumonia, Aspiration
(drug therapy, etiology)
- Pneumonia, Staphylococcal
(drug therapy, etiology)
- Quality-Adjusted Life Years
- Respiration, Artificial
(adverse effects, instrumentation)
- Respiratory Distress Syndrome
(therapy)
- United States
- Vancomycin
(economics, therapeutic use)
- Ventilators, Mechanical
(microbiology)
|